Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Funding will be specifically used to accelerate the clinical development of urcosimod (formerly called OK-101).

Pinguecula is a benign, common degeneration of the conjunctiva that appears as a grey-white-yellow mass on the bulbar ...

Jim Mazzo is among the presenters who will highlight the need to break silos and accelerate eye health solutions at the Collaborative Community on Ophthalmic Innovation (CCOI) meeting at Stanford ...

Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other ...

AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.

Authors noted it may be worthwhile to explore whether oral methylphenidate affects myopia by influencing dopamine levels ...

Alcon’s Voyager is a fully automated, noncontact treatment approach that delivers 120 laser pulses through the limbus of the ...

A Chinese study reveals that secondhand smoke exposure significantly increases the risk of early-onset myopia in children ...

Nanoscope’s BLA has been granted rolling review by the FDA, with the first modules already submitted. The completion of the ...

The FDA accepted Aldeyra's resubmitted NDA for reproxalap after previous rejections due to efficacy concerns, despite no ...